Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. / Holst, Jens Juul; Gromada, Jesper.

In: American Journal of Physiology: Endocrinology and Metabolism, Vol. 287, No. 2, 2004, p. E199-206.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Holst, JJ & Gromada, J 2004, 'Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.', American Journal of Physiology: Endocrinology and Metabolism, vol. 287, no. 2, pp. E199-206. https://doi.org/10.1152/ajpendo.00545.2003

APA

Holst, J. J., & Gromada, J. (2004). Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. American Journal of Physiology: Endocrinology and Metabolism, 287(2), E199-206. https://doi.org/10.1152/ajpendo.00545.2003

Vancouver

Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. American Journal of Physiology: Endocrinology and Metabolism. 2004;287(2):E199-206. https://doi.org/10.1152/ajpendo.00545.2003

Author

Holst, Jens Juul ; Gromada, Jesper. / Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. In: American Journal of Physiology: Endocrinology and Metabolism. 2004 ; Vol. 287, No. 2. pp. E199-206.

Bibtex

@article{d01ba930ab5011ddb5e9000ea68e967b,
title = "Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.",
abstract = "The available evidence suggests that about two-thirds of the insulin response to an oral glucose load is due to the potentiating effect of gut-derived incretin hormones. The strongest candidates for the incretin effect are glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1). In patients with type 2 diabetes, however, the incretin effect is lost or greatly impaired. It is hypothesized that this loss explains an important part of the impaired insulin secretion in patients. Further analysis of the incretin effects in patients has revealed that the secretion of GIP is near normal, whereas the secretion of GLP-1 is decreased. On the other hand, the insulintropic effect of GLP-1 is preserved, whereas the effect of GIP is greatly reduced, mainly because of a complete loss of the normal GIP-induced potentiation of second-phase insulin secretion. These two features, therefore, explain the incretin defect of type 2 diabetes. Strong support for the hypothesis that the defect plays an important role in the insulin deficiency of patients is provided by the finding that administration of excess GLP-1 to patients may completely restore the glucose-induced insulin secretion as well as the beta-cells' sensitivity to glucose. Because of this, analogs of GLP-1 or GLP-1 receptor activations are currently being developed for diabetes treatment, so far with very promising results.",
author = "Holst, {Jens Juul} and Jesper Gromada",
note = "Keywords: Animals; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Neurosecretory Systems; Peptide Fragments; Peptide Hormones; Protein Precursors",
year = "2004",
doi = "10.1152/ajpendo.00545.2003",
language = "English",
volume = "287",
pages = "E199--206",
journal = "American Journal of Physiology: Endocrinology and Metabolism",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "2",

}

RIS

TY - JOUR

T1 - Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.

AU - Holst, Jens Juul

AU - Gromada, Jesper

N1 - Keywords: Animals; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Neurosecretory Systems; Peptide Fragments; Peptide Hormones; Protein Precursors

PY - 2004

Y1 - 2004

N2 - The available evidence suggests that about two-thirds of the insulin response to an oral glucose load is due to the potentiating effect of gut-derived incretin hormones. The strongest candidates for the incretin effect are glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1). In patients with type 2 diabetes, however, the incretin effect is lost or greatly impaired. It is hypothesized that this loss explains an important part of the impaired insulin secretion in patients. Further analysis of the incretin effects in patients has revealed that the secretion of GIP is near normal, whereas the secretion of GLP-1 is decreased. On the other hand, the insulintropic effect of GLP-1 is preserved, whereas the effect of GIP is greatly reduced, mainly because of a complete loss of the normal GIP-induced potentiation of second-phase insulin secretion. These two features, therefore, explain the incretin defect of type 2 diabetes. Strong support for the hypothesis that the defect plays an important role in the insulin deficiency of patients is provided by the finding that administration of excess GLP-1 to patients may completely restore the glucose-induced insulin secretion as well as the beta-cells' sensitivity to glucose. Because of this, analogs of GLP-1 or GLP-1 receptor activations are currently being developed for diabetes treatment, so far with very promising results.

AB - The available evidence suggests that about two-thirds of the insulin response to an oral glucose load is due to the potentiating effect of gut-derived incretin hormones. The strongest candidates for the incretin effect are glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1). In patients with type 2 diabetes, however, the incretin effect is lost or greatly impaired. It is hypothesized that this loss explains an important part of the impaired insulin secretion in patients. Further analysis of the incretin effects in patients has revealed that the secretion of GIP is near normal, whereas the secretion of GLP-1 is decreased. On the other hand, the insulintropic effect of GLP-1 is preserved, whereas the effect of GIP is greatly reduced, mainly because of a complete loss of the normal GIP-induced potentiation of second-phase insulin secretion. These two features, therefore, explain the incretin defect of type 2 diabetes. Strong support for the hypothesis that the defect plays an important role in the insulin deficiency of patients is provided by the finding that administration of excess GLP-1 to patients may completely restore the glucose-induced insulin secretion as well as the beta-cells' sensitivity to glucose. Because of this, analogs of GLP-1 or GLP-1 receptor activations are currently being developed for diabetes treatment, so far with very promising results.

U2 - 10.1152/ajpendo.00545.2003

DO - 10.1152/ajpendo.00545.2003

M3 - Journal article

VL - 287

SP - E199-206

JO - American Journal of Physiology: Endocrinology and Metabolism

JF - American Journal of Physiology: Endocrinology and Metabolism

SN - 0193-1849

IS - 2

ER -

ID: 8418164